Antibe Therapeutics Company Profile (CVE:ATE)

About Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics logoAntibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: C$14.6 million
  • Outstanding Shares: 153,637,000
Average Prices:
  • 52 Week Range: C$0.08 - C$0.29
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Sales & Book Value:
  • Annual Revenue: C$8.7 million
  • Price / Sales: 1.68
  • Book Value: C$0.04 per share
  • Price / Book: 2.64
Profitability:
  • EBIDTA: ($5,580,000.00)
  • Net Margins: -76.30%
  • Return on Equity: -152.57%
  • Return on Assets: -58.65%
Misc:
  • Average Volume: 249,752 shs.
  • Short Ratio: 0.11
 

Frequently Asked Questions for Antibe Therapeutics (CVE:ATE)

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

When will Antibe Therapeutics make its next earnings announcement?

Antibe Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, December, 5th 2017. View Earnings Estimates for Antibe Therapeutics.

Who are some of Antibe Therapeutics' key competitors?

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the folowing people:

  • Walter M. Macnee, Independent Chairman of the Board
  • Daniel Legault J.D., President, Chief Executive Officer, Secretary, Director
  • John L. Wallace Ph.D., Founder, Chief Scientific Officer, Director
  • Alain S Wilson, Chief Financial Officer
  • Jeremy Grushcow, Executive Vice President - Strategic Development
  • David Vaughan, Chief Development Officer
  • Samira Sakhia CPA, Director
  • Yung Wu, Director
  • Roderick J. Flower Ph.D., Independent Director
  • Jonathan Ross Goodman, Independent Director

How do I buy Antibe Therapeutics stock?

Shares of Antibe Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Antibe Therapeutics' stock price today?

One share of Antibe Therapeutics stock can currently be purchased for approximately C$0.10.


MarketBeat Community Rating for Antibe Therapeutics (CVE ATE)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  49
MarketBeat's community ratings are surveys of what our community members think about Antibe Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Antibe Therapeutics (CVE:ATE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Antibe Therapeutics (CVE:ATE)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Antibe Therapeutics (CVE:ATE)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Antibe Therapeutics (CVE:ATE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.01)($0.01)($0.01)
Q4 20181($0.01)($0.01)($0.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Antibe Therapeutics (CVE:ATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Antibe Therapeutics (CVE:ATE)
Insider Trades by Quarter for Antibe Therapeutics (CVE:ATE)
Insider Trades by Quarter for Antibe Therapeutics (CVE:ATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/29/2016Scott Wilson CurtisInsiderBuy19,500C$0.13C$2,535.00
3/28/2016Scott Wilson CurtisInsiderBuy30,500C$0.13C$3,965.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Antibe Therapeutics (CVE:ATE)
Latest Headlines for Antibe Therapeutics (CVE:ATE)
Source:
DateHeadline
businesswire.com logoAntibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI Safety Study for Lead Drug, ATB-346
www.businesswire.com - September 8 at 4:33 PM
americanbankingnews.com logoFY2019 Earnings Estimate for Antibe Therapeutics Inc Issued By Zacks Investment Research (ATE)
www.americanbankingnews.com - September 8 at 1:16 PM
americanbankingnews.com logoZacks Investment Research Weighs in on Antibe Therapeutics Inc's Q2 2018 Earnings (ATE)
www.americanbankingnews.com - September 7 at 11:14 AM
businesswire.com logoAntibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results - Business Wire (press release)
www.businesswire.com - August 29 at 9:24 PM
americanbankingnews.com logoAntibe Therapeutics Inc (ATE) to Release Earnings on Monday
www.americanbankingnews.com - August 21 at 2:32 AM
businesswire.com logoAntibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointestinal Endoscopy Clinical Trial
www.businesswire.com - August 2 at 4:56 PM
businesswire.com logoAntibe Therapeutics Reports 2017 Year-End Financial and Operating Results - Business Wire (press release)
www.businesswire.com - July 28 at 10:24 PM
americanbankingnews.com logoAntibe Therapeutics Inc (CVE:ATE) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 22 at 11:27 AM
businesswire.com logoAntibe Therapeutics Inc. Announces Closing of Public Offering
www.businesswire.com - June 22 at 3:43 PM
businesswire.com logoAntibe Therapeutics Inc. Announces Closing of Public Offering - Business Wire (press release)
www.businesswire.com - June 21 at 4:35 PM
businesswire.com logoAntibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus
www.businesswire.com - June 17 at 3:46 PM
businesswire.com logoAntibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus - Business Wire (press release)
www.businesswire.com - June 16 at 4:24 PM
businesswire.com logoAntibe Therapeutics Inc. Announces Pricing of Offering - Business Wire (press release)
www.businesswire.com - May 26 at 3:57 PM
bizjournals.com logoIIROC Trading Halt - ATE
www.bizjournals.com - May 25 at 1:05 AM
finance.yahoo.com logoResearch Reports Initiated on Healthcare Stocks: OrganiGram Holdings, Aphria, Antibe Therapeutics, and Emerald ... - Yahoo Finance
finance.yahoo.com - May 3 at 10:28 AM
businesswire.com logoAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic - Business Wire (press release)
www.businesswire.com - April 26 at 8:57 PM
businesswire.com logoAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic
www.businesswire.com - April 26 at 3:56 PM
finance.yahoo.com logoAntibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic - Yahoo Finance
finance.yahoo.com - April 26 at 10:03 AM
businesswire.com logoAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference - Business Wire (press release)
www.businesswire.com - April 25 at 3:39 PM
finance.yahoo.com logoAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference - Yahoo Finance
finance.yahoo.com - April 25 at 11:05 AM
businesswire.com logoAntibe Therapeutics to Present at Bloom Burton & Co. Healthcare Investor Conference
www.businesswire.com - April 24 at 3:42 PM
businesswire.com logoAntibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346 - Business Wire (press release)
www.businesswire.com - April 18 at 3:37 PM
businesswire.com logoAntibe Therapeutics Provides Update on Clinical Development Program for Its Lead Drug, ATB-346
www.businesswire.com - April 18 at 9:58 AM
businesswire.com logoAntibe's Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research - Business Wire (press release)
www.businesswire.com - March 28 at 3:39 PM
businesswire.com logoAntibe’s Founder and Chief Scientific Officer to Receive Distinguished Lifetime Achievement Award in Research
www.businesswire.com - March 28 at 11:08 AM
businesswire.com logoAntibe Therapeutics Reports Q3 2017 Interim Financial and Operating Results
www.businesswire.com - March 1 at 8:41 PM
finance.yahoo.com logoIIROC Trading Resumption - ATE
finance.yahoo.com - February 24 at 6:12 PM
businesswire.com logoAntibe Therapeutics Enters into Regional Licensing Deal
www.businesswire.com - February 24 at 6:12 PM
finance.yahoo.com logoAntibe Therapeutics Enters into Regional Licensing Deal - Yahoo Finance
finance.yahoo.com - February 24 at 1:11 PM
businesswire.com logoAntibe Therapeutics Engages MKR Group for US Investor Relations - Business Wire (press release)
www.businesswire.com - February 22 at 11:22 AM
finance.yahoo.com logoAntibe Therapeutics Engages MKR Group for U.S. Investor Relations
finance.yahoo.com - February 21 at 9:46 AM
businesswire.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and ... - Business Wire (press release)
www.businesswire.com - January 31 at 8:53 PM
finance.yahoo.com logoAntibe Therapeutics Announces the Launch of PentOS OI™ Max, Its Newest Bone Graft Substitute for Oral and Maxillofacial Surgery
finance.yahoo.com - January 31 at 3:52 PM
businesswire.com logoAntibe Therapeutics Announces Change of Auditor to Ernst & Young
www.businesswire.com - January 19 at 2:19 AM
businesswire.com logoAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million
www.businesswire.com - December 22 at 2:44 AM
businesswire.com logoAntibe Therapeutics Completes Final Closing of Private Placement Bringing Total Proceeds to $2.7 Million - Business Wire (press release)
www.businesswire.com - December 21 at 9:44 PM
businesswire.com logoAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement - Business Wire (press release)
www.businesswire.com - December 17 at 1:59 AM
businesswire.com logoAntibe Therapeutics Raises $2.4 Million in First Tranche of Private Placement
www.businesswire.com - December 16 at 3:56 PM
businesswire.com logoAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results - Business Wire (press release)
www.businesswire.com - November 30 at 8:42 PM
businesswire.com logoAntibe Therapeutics Reports Q2 2017 Interim Financial and Operating Results
www.businesswire.com - November 30 at 9:21 AM
baystreet.ca logoResearch Reports Initiated on Healthcare Stocks OrganiGram Holdings, Aphria, Antibe Therapeutics, and biOasis Technologies
www.baystreet.ca - November 29 at 4:49 PM
businesswire.com logoAntibe Therapeutics Confirms Non-Addictive Properties for Its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
www.businesswire.com - October 17 at 8:27 AM
businesswire.com logoAntibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics
www.businesswire.com - October 11 at 3:41 PM
businesswire.com logoAntibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference
www.businesswire.com - September 7 at 12:34 PM
businesswire.com logoAntibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results
www.businesswire.com - August 30 at 3:37 PM
finance.yahoo.com logoAntibe Therapeutics Announces the Launch of Neomem® FlexPlus, a High-Performance Barrier Membrane for Oral Surgery
finance.yahoo.com - August 16 at 3:41 PM
businesswire.com logoAntibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis
www.businesswire.com - August 8 at 8:25 AM
finance.yahoo.com logoAntibe Therapeutics Reports 2016 Year-End Financial and Operating Results
finance.yahoo.com - July 29 at 9:05 PM
businesswire.com logoAntibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
www.businesswire.com - July 19 at 9:49 AM
finance.yahoo.com logoAntibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
finance.yahoo.com - June 22 at 8:46 PM

Social

Chart

Antibe Therapeutics (ATE) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff